RNA药物抗乙型肝炎病毒的研究进展

Progress of Studies on Anti-HBV Based on RNA Drugs

乙型肝炎病毒(hepatitis Bvirus,HBV)导致的慢性感染已经成为威胁全球健康的主要问题之一.传统的抗乙肝药物如以拉米夫定和阿德福韦为代表的核苷类似物以及干扰素类药物在临床上都存在一定的局限性,因此寻找新的抗乙肝药物已经成为当务之急.本文主要从小干扰RNA(small interfering RNA,siRNA)、微小RNA(microRNA,miRNA)和配体指数富集的系统进化技术(systematic evolution of ligands by exponential enrichment,SELEX)筛选的RNA适配子这3个方面来分别阐述用小分子RNA药物抗HBV的研究进展和展望.

Chronic hepatitis B virus （HBV） infection has been one of the most serious problems threatening global health. However, currently available clinic treatments against HBV including interferon-α and nucleoside analogs such as lamivudine and adefovir have been proved to be limited successful. Therefore, it is necessary to develop a more effective antiviral therapy with fewer side effects. In this review, we discuss anti-HBV strategies of several small RNA drugs including small interfering RNA （siRNA）, microRNA and nucleic acid aptamers obtained by SELEX （systematic evolution of ligands by exponential enrichment）.